Perspectives on farnesyl transferase inhibitors in cancer therapy

Cancer Letters

Volumn 206, Issue 2, 2004, Pages 159-167

  Mazieres, Julien ^a   Pradines, Anne ^a   Favre, Gilles ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Apoptosis; Cancer therapy; Cell cycle; Chemotherapy; Clinical trials; Farnesyl transferase inhibitors; Ras; Rho

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; CISPLATIN; FLUOROURACIL; GEMCITABINE; L 778123; LONAFARNIB; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; R 11577; RAS PROTEIN; TAXANE DERIVATIVE; TIPIFARNIB;

CANCER THERAPY; CELL FUNCTION; CLINICAL TRIAL; ENZYME ACTIVITY; ENZYME INHIBITION; HEMATOLOGIC MALIGNANCY; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; OXYGENATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRENYLATION; PRIORITY JOURNAL; PROTEIN FUNCTION; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SOLID TUMOR; TUMOR REGRESSION;

EID: 1542328237     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2003.08.033     Document Type: Article

References (68)

1. Zhang F.L., Casey P.J. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65:1996;241-269.
2. Casey P.J. Biochemistry of protein prenylation. J. Lipid Res. 33:1992;1731-1740.
3. Casey P.J., Seabra M.C. Protein prenyltransferases. J. Biol. Chem. 271:1996;5289-5292.
4. Whyte D.B., Kirschmeier P., Hockenberry T.N., NunezOliva I., James L., Catino J.J., et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. 272:1997;14459-14464.
5. Baron R., Fourcade E., Lajoie-Mazenc I., Allal C., Couderc B., Barbaras R., et al. RhoB prenylation is driven by the three carboxyl-terminal amino acids of the protein: evidenced in vivo by an anti-farnesyl cysteine antibody. Proc. Natl. Acad. Sci. USA. 97:2000;11626-11631.
6. Lebowitz P.F., Casey P.J., Prendergast G.C., Thissen J.A. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J. Biol. Chem. 272:1997;15591-15594.
7. Sebti S.M., Hamilton A.D. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues. Expert Opin. Investig. Drugs. 9:2000;2767-2782.
8. James G.L., Goldstein J.L., Brown M.S., Rawson T.E., Somers T.C., Mcdowell R.S., et al. Benzodiazepine peptidomimetics - potent inhibitors of Ras farnesylation in animal cells. Science. 260:1993;1937-1942.
9. Kohl N.E., Mosser S.D., Desolms S.J., Giuliani E.A., Pompliano D.L., Graham S.L., et al. Selective inhibition of Ras-dependent transformation by a farnesyltransferase inhibitor. Science. 260:1993;1934-1937.
10. Manne V., Ricca C.S., Brown J.G., Tuomari A.V., Yan N., Patel D., et al. Ras farnesylation as a target for novel antitumor agents: potent and selective farnesyl diphosphate analog inhibitors of farnesyltransferase. Drug Develop. Res. 34:1995;121-137.
11. Cox A.D., Garcia A.M., Westwick J.K., Kowalczyk J.J., Lewis M.D., Brenner D.A., Der C.J. The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation. J. Biol. Chem. 269:1994;19203-19206.
12. James G.L., Brown M.S., Cobb M.H., Goldstein J.L. Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-Ras-transformed rat-1 cells, but not in untransformed cells. J. Biol. Chem. 269:1994;27705-27714.
13. Sepp-Lorenzino L., Ma Z.P., Bands E., Kohl N.E., Gibbs J.B., Oliff A., Rosen N. Peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res. 55:1995;5302-5309.
14. Lerner E.C., Qian Y.M., Blaskovich M.A., Fossum R.D., Vogt A., Sun J.Z., et al. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J. Biol. Chem. 270:1995;26802-26806.
15. Jiang K., Coppola D., Crespo N.C., Nicosia S.V., Hamilton A.D., Sebti S.M., Cheng J.Q. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol. Cell. Biol. 20:2000;139-148.
16. Nagasu T., Yoshimatsu K., Rowell C., Lewis M.D., Garcia A.M. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res. 55:1995;5310-5314.
17. Law B.K., Norgaard P., Gnudi L., Kahn B.B., Poulson H.S., Moses H.L. Inhibition of DNA synthesis by a farnesyltransferase inhibitor involves inhibition of the p70(s6k) pathway. J. Biol. Chem. 274:1999;4743-4748.
18. Miquel K., Pradines A., Sun J., Qian Y., Hamilton A.D., Sebti S.A., Favre G. GGTI-298 induces G0/G1 block and apoptosis whereas FTI-277 causes G2/M enrichment in A549 cells. Cancer Res. 57:1997;1846-1850.
19. Vogt A., Sun J.Z., Qian Y.M., Hamilton A.D., Sebti S.M. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G(0)/G(1) and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. J. Biol. Chem. 272:1997;27224-27229.
20. Ashar H.R., James L., Gray K., Carr D., McGuirk M., Maxwell E., et al. The farnesyl transferase inhibitor SCH 66336 induces a G(2)→M or G(1) pause in sensitive human tumor cell lines. Exp. Cell Res. 262:2001;17-27.
21. Tamanoi F., Gau C.L., Jiang C., Edamatsu H., Kato-Stankiewicz J. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells. Cell. Mol. Life Sci. 58:2001;1636-1649.
22. Sepp-Lorenzino L., Rosen N. A farnesyl-protein transferase inhibitor induces p21 expression and G(1) block in p53 wild type tumor cells. J. Biol. Chem. 273:1998;20243-20251.
23. Mazzocca A., Giusti S., Hamilton A.D., Sebti S.M., Pantaleo P., Carloni V. Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines. Mol. Pharmacol. 63:2003;159-166.
24. Crespo N.C., Ohkanda J., Yen T.J., Hamilton A.D., Sebti S.M. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J. Biol. Chem. 276:2001;16161-16167.
25. Crespo N.C., Delarue F., Ohkanda J., Carrico D., Hamilton A.D., Sebti S.M. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status. Cell Death Differ. 9:2002;702-709.
26. Suzuki N., Urano J., Tamanoi F. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc. Natl. Acad. Sci. USA. 95:1998;15356-15361.
27. Rose W.C., Lee F.Y., Fairchild C.R., Lynch M., Monticello T., Kramer R.A., Manne V. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res. 61:2001;7507-7517.
28. Lebowitz P.F., Sakamuro D., Prendergast G.C. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res. 57:1997;708-713.
29. Brassard D.L., English J.M., Malkowski M., Kirschmeier P., Nagabhushan T.L., Bishop W.R. Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras. Exp. Cell Res. 273:2002;138-146.
30. Liu M., Bryant M.S., Chen J., Lee S., Yaremko B., Lipari P., et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res. 58:1998;4947-4956.
31. Barrington R.E., Subler M.A., Rands E., Omer C.A., Miller P.J., Hundley J.E., et al. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol. Cell. Biol. 18:1998;85-92.
32. Sun J.Z., Qian Y.M., Hamilton A.D., Sebti S.M. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res. 55:1995;4243-4247.
33. Lantry L.E., Zhang Z., Yao R., Crist K.A., Wang Y., Ohkanda J., et al. Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis. 21:2000;113-116.
34. Kohl N.E., Omer C.A., Conner M.W., Anthony N.J., Davide J.P., Desolms S.J., et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med. 1:1995;792-797.
35. Lerner E.A., Zhang T.-T., Knowles D.B., Qian Y., Hamilton A.D., Sebti S.M. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitors in human tumor cell lines. Oncogene. 15:1997;1283-1288.
36. Prendergast G.C., Davide J.P., Desolms S.J., Giuliani E.A., Graham S.L., Gibbs J.B., et al. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol. Cell. Biol. 14:1994;4193-4202.
37. Lebowitz P.F., Davide J.P., Prendergast G.C. Evidence that farnesyltransferase inhibitors suppress ras transformation by interfering with rho activity. Mol. Cell. Biol. 15:1995;6613-6622.
38. Du W., Lebowitz P.F., Prendergast G.C. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol. Cell. Biol. 19:1999;1831-1840.
39. Chen Z., Sun J., Pradines A., Favre G., Adnane J., Sebti S.M. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation, induce apoptosis and suppress human tumor growth in nude mice. J. Biol. Chem. 275:2000;17974-17978.
40. Johnston S.R. Farnesyl transferase inhibitors: a novel targeted therapy for cancer. Lancet Oncol. 2:2001;18-26.
41. Haluska P., Dy G.K., Adjei A.A. Farnesyl transferase inhibitors as anticancer agents. Eur. J. Cancer. 38:2002;1685-1700.
42. Johnston S.R., Kelland L.R. Farnesyl transferase inhibitors - a novel therapy for breast cancer. Endocr. Relat. Cancer. 8:2001;227-235.
43. Cortes J.E., Albitar M., Thomas D., Giles F., Kurzrock R., Thibault A., et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematological malignancies. Blood. 101:2003;1692-1697.
44. Cloughesy T., Kuhn J., Wen P., Changh S., Schiff D., Greenberg I., et al. Phase II trial of R115777 (Zarnestra) in patients with recurrent glioma not taking enzyme inducing antiepileptic drugs (EIAED): a North American Brain Tumor Consortium (NABTC) report. Proc. Am. Soc. Clin. Oncol. 2002;A317.
45. Cunningham D., De Gramont A., Scheithauer W., Smakal M., Humblet Y., Kurteva G., et al. Randomized double-blind placebo-controlled trial of the farnseyltransferase inhibitor R115777 (Zarnestra) in advanced refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol. 2002;A502.
46. Adjei A.A., Davis J.N., Erlichman C., Svingen P.A., Kaufmann S.H. Comparison of potential markers of farnesyltransferase inhibition. Clin. Cancer Res. 6:2000;2318-2325.
47. Du W., Liu A., Prendergast G.C. Activation of the PI3′K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors. Cancer Res. 59:1999;4208-4212.
48. Sun J., Blaskovich M.A., Knowles D., Qian Y., Ohkanda J., Bailey R.D., et al. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, taxol, and gemcitabine. Cancer Res. 59:1999;4919-4926.
49. Moasser M.M., SeppLorenzino L., Kohl N.E., Oliff A., Balog A., Su D.S., et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc. Natl. Acad. Sci. USA. 95:1998;1369-1374.
50. Sepp-Lorenzino L., Balog A., Su D.S., Meng D., Timaul N., Scher H.I., et al. The microtubule-stabilizing agents epothilones A and B and their desoxy-derivatives induce mitotic arrest and apoptosis in human prostate cancer cells. Prostate Cancer Prostatic Dis. 2:1999;41-52.
51. Zhang B., Prendergast G.C., Fenton R.G. Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. Cancer Res. 62:2002;450-458.
52. Khuri F., Glisson B., Meyers M., Herbst R., Thall P., Munden R., et al. Proc. Am. Soc. Clin. Oncol. 2000;A799.
53. Van Cutsem E., Karasek P., Oettle H., Vervenne W., Szawlowski A., Schoffski P., et al. Phase III trial comparing gemcitabine+R115777 (Zarnestra) versus gemcitabine+placebo in advanced pancreatic cancer (PC). Proc. Am. Soc. Clin. Oncol. 2002;A517.
54. Cohen-Jonathan E., Toulas C., Ader I., Monteil S., Allal C., Bonnet J., et al. The farnesyl transferase inhibitor FTI-277 suppresses the 24 kDa bFGF-induced radioresistance in HeLa cells expressing wild type Ras. Radiat. Res. 152:1999;404-411.
55. Bernhard E.J., McKenna W.G., Hamilton A.D., Sebti S.M., Qian Y., Wu J.M., Muschel R.J. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res. 58:1998;1754-1761.
56. Delmas C., Heliez C., Cohen-Jonathan E., End D., Bonnet J., Favre G., Toulas C. The farnesyltransferase inhibitor, R115777, radiosensitizes radioresistant human glioma cell lines. Int. J. Cancer. 100:2002;43-48.
57. Cohen-Jonathan E., Evans S.M., Koch C.J., Muschel R.J., McKenna W.G., Wu J., Bernhard E.J. The farnesyltransferase inhibitor L744, 832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res. 61:2001;2289-2293.
58. Hahn S.M., Bernhard E.J., Regine W., Mohiuddin M., Haller D.G., Stevenson J.P., et al. A Phase I trial of the farnesyltransferase inhibitor L-778, 123 and radiotherapy for locally advanced lung and head and neck cancer. Clin. Cancer Res. 8:2002;1065-1072.
59. End D.W., Smets G., Todd A.V., Applegate T.L., Fuery C.J., Angibaud P., et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 61:2001;131-137.
60. Edamatsu H., Gau C.L., Nemoto T., Guo L., Tamanoi F. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene. 19:2000;3059-3068.
61. Schwartz G.K., O'Reilly E., Ilson D., Saltz L., Sharma S., Tong W., et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J. Clin. Oncol. 20:2002;2157-2170.
62. Hoover R.R., Mahon F.X., Melo J.V., Daley G.Q. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood. 100:2002;1068-1071.
63. Schwartz G., Rowinsky E.K., Rha S.Y., Hammond L.A., Smith L., Patnaik A., et al. A Phase I, pharmacokinetic, and biologic correlative study of R115777 and trastuzumab (herceptin) in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. 2001;A322.
64. Su Z.Z., Austin V.N., Zimmer S.G., Fisher P.B. Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-ras-transformed cloned rat embryo fibroblast cells. Oncogene. 8:1993;1211-1219.
65. Sebti S.M., Hamilton A.D. Inhibition of Ras prenylation: a novel approach to cancer chemotherapy. Pharmacol. Ther. 74:1997;103-114.
66. Lobell R.B., Omer C.A., Abrams M.T., Bhimnathwala H.G., Brucker M.J., Buser C.A., et al. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res. 61:2001;8758-8768.
67. Johnston S.R., Head J., Pancholi S., Detre S., Martin L.A., Smith I.E., Dowsett M. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin. Cancer Res. 9:2003;524S-532S.
68. Sepp-Lorenzino L., Tjaden G., Moasser M.M., Timaul N., Ma Z., Kohl N.E., et al. Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancer. Prostate Cancer Prostatic Dis. 4:2001;33-43.